ESKATA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eskata, and what generic alternatives are available?
Eskata is a drug marketed by Aclaris and is included in one NDA. There are six patents protecting this drug.
This drug has thirty-one patent family members in eighteen countries.
The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.
DrugPatentWatch® Generic Entry Outlook for Eskata
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 8, 2022. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ESKATA
International Patents: | 31 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 145 |
Patent Applications: | 4,138 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ESKATA? | ESKATA excipients list |
DailyMed Link: | ESKATA at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ESKATA
Generic Entry Date for ESKATA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for ESKATA
US Patents and Regulatory Information for ESKATA
ESKATA is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ESKATA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ESKATA
Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Seborrheic keratosis treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ESKATA
See the table below for patents covering ESKATA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 100508990 | See Plans and Pricing | |
Japan | 6622217 | See Plans and Pricing | |
World Intellectual Property Organization (WIPO) | 02064151 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ESKATA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2523731 | LUC00159 | Luxembourg | See Plans and Pricing | PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113 |
2523731 | CA 2020 00025 | Denmark | See Plans and Pricing | PRODUCT NAME: OSILODROSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER OSILODROSTATDIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200113 |
2523731 | 2020012 | Norway | See Plans and Pricing | PRODUCT NAME: OSILODROSTAT ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV, INKLUDERT OSILODROSTAT DIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |